跳至主要内容
临床试验/NCT00212719
NCT00212719已完成3 期

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Ono Pharmaceutical Co., Ltd.0 个研究点目标入组 250 人开始时间: 2003年5月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
250
主要终点
Mean bone mineral density of the lumbar spine (L2-4 BMD)

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • A diagnosis in accordance with Criteria for the Diagnosis of Primary Osteoporosis.
  • Other inclusion criteria as specified in the study protocol.

排除标准

  • Patients having secondary osteoporosis or another condition that presents low bone mass.
  • Patients having findings that affect measurement of lumbar spinal bone mineral density by DXA
  • Patients that have been administered bisphosphonate derivatives.
  • Other exclusion criteria as specified in the study protocol.

结局指标

主要结局

Mean bone mineral density of the lumbar spine (L2-4 BMD)

次要结局

  • Bone mineral density at femur, fragility fractures, biochemical markers of bone turnover, lower back pain

研究者

申办方类型
Industry
责任方
Sponsor

相似试验